Golodirsen (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "Golodirsen" in English language version.
Last modified:
Ref.Un. Ref.Website
Global rank
English rank
1st place
1st place
15th place
8th place
low place
low place
low place
6,244th place
biopharmadive.com (Global: low place; English: low place)
- "Safety risks highlighted in FDA letter on Sarepta's Vyondys". BioPharma Dive. 22 January 2020. Archived from the original on 23 January 2020. Retrieved 22 January 2020.
biospace.com (Global: low place; English: 6,244th place)
- Terry M (22 January 2020). "FDA Publishes Initial Rejection Letter of Sarepta's Vyondys 53 for DMD". BioSpace. Archived from the original on 2 March 2020. Retrieved 22 January 2020.
doi.org (Global: 2nd place; English: 2nd place)
fda.gov (Global: 470th place; English: 329th place)
fda.gov
- "FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation". U.S. Food and Drug Administration (FDA) (Press release). 12 December 2019. Archived from the original on 13 December 2019. Retrieved 12 December 2019.
This article incorporates text from this source, which is in the public domain. - "Drug Trials Snapshots: Vyondys 53". U.S. Food and Drug Administration (FDA). 12 December 2019. Archived from the original on 26 September 2020. Retrieved 24 January 2020. This article incorporates text from this source, which is in the public domain.
accessdata.fda.gov
- Unger EF (19 August 2019). "NDA 211970 Other action letter" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 25 February 2020. Retrieved 22 January 2020.
- "Drug Approval Package: Vyondys 53 (golodirsen)". U.S. Food and Drug Administration (FDA). 21 January 2020. Archived from the original on 2 March 2020. Retrieved 22 January 2020.
nih.gov (Global: 5th place; English: 5th place)
dailymed.nlm.nih.gov
- "Vyondys 53- golodirsen injection". DailyMed. 31 March 2020. Archived from the original on 23 October 2020. Retrieved 6 August 2020.
pubmed.ncbi.nlm.nih.gov
semanticscholar.org (Global: 15th place; English: 8th place)
api.semanticscholar.org
web.archive.org (Global: 1st place; English: 1st place)
- "Vyondys 53- golodirsen injection". DailyMed. 31 March 2020. Archived from the original on 23 October 2020. Retrieved 6 August 2020.
- "FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation". U.S. Food and Drug Administration (FDA) (Press release). 12 December 2019. Archived from the original on 13 December 2019. Retrieved 12 December 2019. This article incorporates text from this source, which is in the public domain.
- "Safety risks highlighted in FDA letter on Sarepta's Vyondys". BioPharma Dive. 22 January 2020. Archived from the original on 23 January 2020. Retrieved 22 January 2020.
- Terry M (22 January 2020). "FDA Publishes Initial Rejection Letter of Sarepta's Vyondys 53 for DMD". BioSpace. Archived from the original on 2 March 2020. Retrieved 22 January 2020.
- Unger EF (19 August 2019). "NDA 211970 Other action letter" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 25 February 2020. Retrieved 22 January 2020.
- "Drug Approval Package: Vyondys 53 (golodirsen)". U.S. Food and Drug Administration (FDA). 21 January 2020. Archived from the original on 2 March 2020. Retrieved 22 January 2020.
- "Drug Trials Snapshots: Vyondys 53". U.S. Food and Drug Administration (FDA). 12 December 2019. Archived from the original on 26 September 2020. Retrieved 24 January 2020. This article incorporates text from this source, which is in the public domain.